Chipscreen Biosciences, Ltd.

This phase 3 trial tests a new combination of drugs (chiauranib, an immunotherapy, and two chemotherapies) as a first treatment for people with metastatic pancreatic cancer that has spread. About 558 adults will take part to see if the combo helps them live longer and controls th…

This early-phase study tests a new drug called CS08399 in people with advanced solid tumors or lymphoma that have a missing MTAP gene. The main goals are to find a safe dose and see how the drug works in the body. About 186 adults will take part, and the study will also check if …

This study looks at adding a drug called Chiglitazar to standard SGLT-2 inhibitor treatment for adults with type 2 diabetes whose blood sugar is not well controlled. Researchers will track blood sugar levels, heart, kidney, and liver health over time. The goal is to see if this c…

This study checks if a new tablet that combines two diabetes medicines (Chiglitazar and Metformin) works the same as taking them separately. It involves 24 healthy adults who take a single dose of each version under fed conditions. The goal is to measure how the drug moves throug…

This study checks if a new tablet that combines two diabetes drugs (chiglitazar and metformin) works the same as the standard separate pills. It involves 64 healthy adults aged 18-45 who take a single dose of each version under fed conditions. The goal is to compare how the body …

This early-stage study tests a new extended-release tablet that combines two diabetes drugs (Chiglitazar and Metformin) in 28 healthy Chinese adults. The goal is to see how a high-fat meal changes drug levels and how the body processes the drug after multiple doses. Participants …